Oral small molecule GLP-1 receptor agonist
Danuglipron 2.5 mg tablet twice daily
DANU_PO_2p5MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 200 mg oral twice daily
- Danuglipron 80 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.71 (0.01 to 58.74) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.52 (0.09 to 17.52) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.91 (0.06 to 8.80) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.63 (0.04 to 5.20) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.39 (0.06 to 1.75) | 0.83 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.08 (0.52 to 8.75) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.19 (0.00 to 3.05) | 0.89 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.13 (0.21 to 5.27) | 0.61 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.53 (0.01 to 26.47) | 0.60 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.87 (0.05 to 13.17) | 0.47 |